Skip to content

Depression: all studies

Page 593 of 1,034: studies 5,921 to 5,930 of 10,336, newest first. Back to the depression overview

Research

Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.

Disease-a-month : DM March 1, 2025 Andrew M Farrar, Isabelle H Nordstrom, Kaitlyn Shelley et al. 7 citations

3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and...

[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].

Der Nervenarzt March 1, 2025 Moritz Spangemacher, Jonathan R Reinwald, Hana Adolphi et al.

Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology. What could be the shared effects of various antidepressants and in this context what role do extrapharmacological factors, such as the body and environment, play? The available literature on clinical and preclinical data for assumed combined active factors of...

The ketamine chameleon: history, pharmacology, and the contested value of experience.

Expert Review of Clinical Pharmacology March 1, 2025 Danny Diep, Sara de la Salle, Julien Thibault Lévesque et al. 8 citations

Since its synthesis in 1962, ketamine has been widely used in diverse medical contexts, from anesthesia to treatment-resistant depression. However, interpretations of ketamine's subjective effects remain polarized. Biomedical frameworks typically construe the drug's experiential effects as dissociative or psychotomimetic, while psychedelic paradigms emphasize the potential therapeutic merits of...

Effects of Chronic Social Isolation Stress and Alcohol on the Reinforcing Properties of Ketamine in Male and Female Rats.

eNeuro March 1, 2025 Sarah D Jennings, Devin P Hagarty, Jordan Logue et al. 1 citation

While ketamine, an NMDA receptor antagonist, is effective in treating major depression, studies have not addressed the safety of repeated ketamine infusions in depressed patients with comorbid alcohol use disorder (AUD). In this study, we aimed to determine whether a history of chronic social isolation and alcohol exposure alter the reinforcing properties of ketamine in male and female rats....

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.

Molecular Psychiatry March 1, 2025 Michel Sabé, Adi Sulstarova, Alban Glangetas et al. 39 citations

Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of...

DOI: 10.1038/s41380-024-02800-5 (opens in new tab) Full text (opens in new tab) Schizophrenia Psychedelics Mental health Drug safety +1

Psychedelic-assisted therapy: An overview for the internist

Cleveland Clinic Journal of Medicine March 1, 2025 Franklin King, Brian S. Barnett, Erin Mauney 11 citations

Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy

Cancer Medicine March 1, 2025 Erika Belitzky, Lis Victoria Ravani Carvalho, Melissa Taylor et al. 5 citations

ABSTRACT Purpose To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychological distress. Content Pain is a common symptom of cancer and treatment. However, there are high rates of undertreatment of cancer pain due to the complex underlying biology of the condition, and potentially due to a decrease in opioid prescribing in...

The Spiritual Lifestyle of BrahmaKumaris through RajYoga Meditation

Scholastic Medical Sciences February 28, 2025

Raj Yoga Meditation represents the pillars that hold up our sustainable future. It is clear that many industries and research of many academics rec- ognize the significance of meditation. Raja Yoga meditation is a form of meditation that’s mentioned in the Bhagavad Gita and subsequently popu- larized in the 19th century by Swami Vivekananda. It has continued to gain widespread popularity and is...

Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample

February 28, 2025 Dan Petrovitch, Samuel Hosford, Andrew K. Littlefield et al. preprint

Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional psychotherapy. Despite limited formal regulatory approval, treatment seekers can currently access PAT through a variety of avenues, including ketamine treatment centers and “supported adult use” psilocybin centers in the U.S., drug tourism,...

DOI: 10.31234/osf.io/26tz7_v1 (opens in new tab) Sample material Latent class model Cross-sectional study Nonprobability sampling +4

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Clinical Pharmacology & Therapeutics February 28, 2025 Lorenz Mueller, Alen Jelusic, Avram Tolev et al. 15 citations

Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days,...

DOI: 10.1002/cpt.3618 (opens in new tab) Pharmacokinetics Placebo Double blind Pharmacology +5